{"gene":"ABHD12","run_date":"2026-06-09T22:02:37","timeline":{"discoveries":[{"year":2010,"finding":"ABHD12 was identified as the gene mutated in PHARC disease, and the encoded enzyme hydrolyzes 2-arachidonoylglycerol (2-AG), the main endocannabinoid lipid transmitter acting on cannabinoid receptors CB1 and CB2, establishing PHARC as an inborn error of endocannabinoid metabolism.","method":"Human genetics (mutation identification) combined with published biochemical data on 2-AG hydrolase activity","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic causation established in 19 patients across four countries, combined with enzymatic function replicated independently across multiple subsequent studies","pmids":["20797687"],"is_preprint":false},{"year":2011,"finding":"ABHD12 is highly expressed in microglia and accounts for approximately 9% of total brain 2-AG hydrolase activity, positioning it as a serine hydrolase that degrades the endocannabinoid 2-AG in the brain.","method":"Activity-based biochemical assays of brain 2-AG hydrolase activity combined with expression profiling","journal":"Acta physiologica (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative enzyme activity assays in brain tissue, replicated in subsequent biochemical characterization papers, but review article compiling data","pmids":["21418147"],"is_preprint":false},{"year":2012,"finding":"Human ABHD12 is a genuine monoacylglycerol (MAG) lipase with preference for the 1(3)- and 2-isomers of arachidonoylglycerol; the catalytic triad residues S246-D333-H372 are essential for enzymatic activity and for labeling by the active-site serine-directed probe TAMRA-FP, as shown by site-directed mutagenesis abolishing both activity and probe labeling.","method":"Fluorescent glycerol assay with recombinant human ABHD12; site-directed mutagenesis of catalytic triad; activity-based protein profiling with TAMRA-FP","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis of catalytic residues, multiple orthogonal methods (fluorescent assay + ABPP probe) in a single study","pmids":["22969151"],"is_preprint":false},{"year":2013,"finding":"ABHD12 is a principal lysophosphatidylserine (LPS) lipase in the mammalian brain; recombinant ABHD12 exhibits robust LPS lipase activity, ABHD12-/- mice show massive accumulation of very-long-chain LPS lipids that are TLR2 activators, and loss of ABHD12 leads to microglial activation followed by auditory and motor defects resembling PHARC.","method":"Untargeted metabolomics of ABHD12-/- mouse brain; recombinant protein LPS lipase activity assay; genetic mouse model with behavioral phenotyping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted enzymatic activity with recombinant protein, validated in knockout mouse metabolomics, multiple orthogonal methods, replicated by subsequent studies","pmids":["23297193"],"is_preprint":false},{"year":2013,"finding":"Loss-of-function mutations in ABHD12 result in absence of ABHD12 hydrolase activity as measured by activity-based protein profiling (ABPP) of serine hydrolases in patient-derived lymphoblastoid cell lines, and heterozygous deletion causes ~50% reduction in ABHD12 activity, confirming that mutations directly impair enzyme function.","method":"Activity-based protein profiling (ABPP) of serine hydrolases in patient-derived lymphoblastoid cell lines; quantitative RT-PCR","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ABPP in patient cells with quantitative activity measurement, two orthogonal methods (ABPP + qRT-PCR), single lab","pmids":["24027063"],"is_preprint":false},{"year":2015,"finding":"ABHD16A functions as a phosphatidylserine (PS) lipase that generates lyso-PS in mammalian systems, and ABHD12 degrades lyso-PS; these two enzymes form an ABHD16A-ABHD12 axis that dynamically regulates lyso-PS metabolism in vivo. In mouse macrophages, disruption of ABHD12 increases lyso-PS levels and enhances LPS-induced cytokine production, while ABHD16A disruption has the opposite effect.","method":"Activity-based protein profiling; pharmacological inhibition; genetic knockouts (Abhd12-/- and Abhd16a-/- mice); lipidomics; cytokine measurements in macrophages","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (ABPP, pharmacology, genetics, lipidomics, functional immunological assays), two knockout mouse models, independent validation","pmids":["25580854"],"is_preprint":false},{"year":2016,"finding":"ABHD12 mutations (T253R, T202I, R352*) abolish monoacylglycerol lipase activity in transfected HEK293 cells; knockdown of zebrafish abhd12 causes myelination defects, progressive ataxia, motor impairment, retinal architecture disruption, lens clarification inhibition, and reduced mechanosensory hair cells — phenotypes rescued by wild-type human ABHD12 mRNA but not by mutation-harboring mRNAs.","method":"MAG lipase activity assay in transfected HEK293 cells; zebrafish morpholino knockdown; mRNA rescue experiments with wild-type vs. mutant ABHD12","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic activity assay with disease mutations, zebrafish loss-of-function with specific phenotypes, and rescue with wild-type vs. mutant mRNA as functional validation","pmids":["27890673"],"is_preprint":false},{"year":2018,"finding":"ABHD12 requires glycosylation for optimal enzymatic activity and has a strong preference for very-long-chain lipid substrates; ABHD12 is enriched on the endoplasmic reticulum membrane, as shown by cellular organelle fractionation and immunofluorescence, explaining the accumulation of very-long-chain LPS lipids in ABHD12 knockout mouse brains.","method":"Biochemical substrate profiling with a lipid library of varying chain lengths; cellular organelle fractionation; immunofluorescence; validation in brain membrane lysates from WT and ABHD12-/- mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with substrate library, subcellular fractionation with functional consequence (ER localization explaining VLC lipid accumulation), validated in knockout mouse tissue","pmids":["30237167"],"is_preprint":false},{"year":2018,"finding":"Pharmacological inhibition of ABHD12 with the selective inhibitor DO264 elevates lyso-PS in mouse brain and primary human macrophages, and both DO264-treated and ABHD12-/- mice display heightened immunological responses to LCMV infection with severe lung pathology and elevated proinflammatory chemokines, demonstrating that ABHD12 regulates immunostimulatory lyso-PS lipid pathways in vivo.","method":"Selective small-molecule inhibitor (DO264) in vivo; ABHD12-/- mice; viral infection model (LCMV); lipidomics; cytokine/chemokine measurements","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological and genetic approaches with concordant results, in vivo lipidomics, immune functional readouts, replicated across two independent perturbation strategies","pmids":["30420694"],"is_preprint":false},{"year":2019,"finding":"ABHD12 hydrolyzes oxidized phosphatidylserine (ox-PS), a proapoptotic 'eat me' signal generated under oxidative stress; this activity was identified via a chemical-genetic screen and validated in primary peritoneal macrophages and brains from Abhd12-/- mice under inflammatory stress.","method":"Chemical-genetic screen using a ROS-generating small molecule; lipidomics; validation in primary macrophages and Abhd12-/- mouse brain under inflammatory conditions","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — unbiased chemical-genetic screen combined with in vitro and in vivo validation in knockout mice, multiple orthogonal methods","pmids":["30643283"],"is_preprint":false},{"year":2019,"finding":"ABHD12 acts on both lysophosphatidylserine (lyso-PS) and lysophosphatidylinositol (lyso-PI) as substrates; the selective inhibitor DO264 augments inflammatory cytokine production from human THP-1 macrophage cells, confirming that ABHD12 enzymatic activity suppresses innate immune responses.","method":"Activity-based protein profiling (ABPP)-guided inhibitor development; substrate assays with lyso-PS and lyso-PI; cytokine production assay in human THP-1 macrophages","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ABPP-guided pharmacology with functional immune readout, but substrate specificity for lyso-PI not independently replicated at same rigor","pmids":["30720278"],"is_preprint":false},{"year":2020,"finding":"Genetic deletion of the lysophospholipid acyltransferase LPCAT3 blocks accumulation of brain arachidonoyl (C20:4) PS in ABHD12-/- mice while producing hyper-increases in lyso-PS, demonstrating that ABHD12 and LPCAT3 coordinately regulate lyso-PS and C20:4 PS content in the CNS through a Lands cycle-like remodeling pathway; lyso-PS lipids are identified as likely bioactive metabolites contributing to PHARC neuropathologies.","method":"Double-knockout mouse model (ABHD12-/- × LPCAT3-/-); brain lipidomics; auditory function testing; microgliosis assessment","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis using double-knockout mice with lipidomics and functional phenotyping, multiple orthogonal readouts in a single rigorous study","pmids":["32364701"],"is_preprint":false},{"year":2020,"finding":"Pharmacological inhibition or genetic disruption of ABHD12 potentiates ferroptosis in HT1080 cancer cells induced by the GPX4 inhibitor RSL3; ABHD12-inactivated cells show elevated lyso-PS, increased arachidonate (C20:4)-containing PS, and elevated 2-AG, identifying ABHD12 as a regulator of ferroptotic sensitivity through oxidation-sensitive lipid mediators.","method":"Small-molecule screen with serine hydrolase inhibitors; ABHD12 genetic disruption; metabolomics in RSL3-treated cells; ferroptosis cell death assays","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic approaches with metabolomic validation, but ferroptosis mechanism is partially characterized in a single lab study","pmids":["32195565"],"is_preprint":false},{"year":2020,"finding":"Using immunohistochemistry with ABHD16A and ABHD12 knockout mice as controls, ABHD12 and ABHD16A are shown to localize to distinct regions and cell types in the cerebellum; cerebellar lyso-PS levels are most affected by deletion of ABHD12 (increased) or ABHD16A (decreased), establishing the cerebellum as the brain region where the ABHD16A-ABHD12 lyso-PS axis is most active.","method":"Immunohistochemistry with knockout mouse controls; subcellular organelle fractionation; mass spectrometry-based quantitative lipidomics of brain regions","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with genetic controls plus quantitative regional lipidomics, but single lab study","pmids":["32462874"],"is_preprint":false},{"year":2024,"finding":"Neuronal overexpression of ABHD12 (a PS lipase) suppresses macrophage activation, preserves motor axon integrity, and rescues motor function in a chronic SARM1-activation (sarmopathy) mouse model, demonstrating that ABHD12-mediated PS metabolism regulates phagocyte-mediated axon elimination downstream of SARM1 activation.","method":"Transgenic neuronal overexpression of ABHD12 in NMNAT2 hypomorphic mouse model; motor function behavioral assays; axon morphology analysis; macrophage activation assessment","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain-of-function with functional rescue and mechanistic pathway placement, but single lab study with published and preprint versions","pmids":["40496808","38979309"],"is_preprint":false},{"year":2026,"finding":"In microglia, ABHD12 activity is uncoupled from transcript and protein expression levels (indicative of post-translational regulation); cellular ABHD12 activity inversely correlates with 2-AG levels, and pharmacological inhibition of ABHD12 elevates 2-AG, reduces arachidonic acid (AA), and modulates cytokine release through dual mechanisms: CB2R-dependent suppression of TNF-α and PGE2-dependent regulation of IL-6.","method":"Activity-based protein profiling (ABPP) with tailored probe LEI-612; targeted lipidomics across microglial states; pharmacological inhibition with DO264; CB2R antagonism; cytokine measurements","journal":"ACS chemical neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ABPP with tailored probe combined with lipidomics and pharmacological dissection of downstream signaling, multiple orthogonal methods in single lab study","pmids":["41983263"],"is_preprint":false}],"current_model":"ABHD12 is an integral membrane serine hydrolase (catalytic triad S246-D333-H372) localized to the endoplasmic reticulum that functions as a principal lysophosphatidylserine (lyso-PS) lipase with preference for very-long-chain and arachidonoyl-containing substrates, also hydrolyzing 2-arachidonoylglycerol (2-AG) and oxidized phosphatidylserine; it acts in an ABHD16A-ABHD12 metabolic axis that dynamically regulates lyso-PS levels in the brain (particularly cerebellum), and its loss leads to accumulation of proinflammatory TLR2-activating lyso-PS lipids, microglial activation, and the progressive PHARC neuropathology, while its activity in microglia is post-translationally regulated and controls 2-AG-mediated immunosuppression via CB2R and PGE2 pathways."},"narrative":{"mechanistic_narrative":"ABHD12 is an integral endoplasmic reticulum membrane serine hydrolase that degrades bioactive lysophospholipids and endocannabinoids, thereby controlling neuroinflammation and the lipid signals that drive PHARC neuropathology [PMID:20797687, PMID:23297193, PMID:30237167]. Catalysis depends on a serine hydrolase triad (S246-D333-H372), whose mutation abolishes both enzymatic activity and active-site probe labeling [PMID:22969151]. Although first characterized as a 2-arachidonoylglycerol (2-AG) hydrolase that contributes to brain endocannabinoid turnover [PMID:20797687, PMID:21418147, PMID:22969151], its principal physiological role is as a lysophosphatidylserine (lyso-PS) lipase with strong preference for very-long-chain substrates, a selectivity reinforced by its glycosylation-dependent activity and ER localization [PMID:23297193, PMID:30237167]; it additionally hydrolyzes oxidized phosphatidylserine and lysophosphatidylinositol [PMID:30643283, PMID:30720278]. ABHD12 operates within an ABHD16A-ABHD12 axis—ABHD16A generating lyso-PS and ABHD12 degrading it—that dynamically sets lyso-PS tone, most prominently in the cerebellum, and coordinates with the Lands-cycle remodeler LPCAT3 to balance lyso-PS and arachidonoyl-PS pools [PMID:25580854, PMID:32364701, PMID:32462874]. Loss of ABHD12 causes accumulation of proinflammatory TLR2-activating lyso-PS lipids, microglial activation, and progressive auditory and motor defects modeling PHARC, and ABHD12 was identified as the gene mutated in PHARC disease [PMID:20797687, PMID:23297193]. Functionally, ABHD12 restrains innate immune and phagocyte responses: its activity suppresses inflammatory cytokine production, modulates ferroptotic sensitivity, regulates phagocyte-mediated axon elimination downstream of SARM1, and in microglia is post-translationally controlled to govern 2-AG-mediated immunosuppression via CB2R and PGE2 pathways [PMID:30420694, PMID:32195565, PMID:40496808, PMID:38979309, PMID:41983263].","teleology":[{"year":2010,"claim":"Establishing the disease link and an enzymatic activity converted an uncharacterized gene into a defined inborn error of lipid metabolism, framing PHARC as a hydrolase deficiency.","evidence":"Human genetics mutation identification combined with biochemical 2-AG hydrolase data","pmids":["20797687"],"confidence":"High","gaps":["Did not establish which lipid substrate is pathophysiologically relevant","No subcellular localization or structural detail"]},{"year":2012,"claim":"Defining the catalytic triad and confirming monoacylglycerol lipase activity pinned the molecular basis of catalysis and licensed activity-based profiling of the enzyme.","evidence":"Recombinant human ABHD12 fluorescent glycerol assay, catalytic-triad mutagenesis, and TAMRA-FP activity-based profiling","pmids":["22969151"],"confidence":"High","gaps":["Did not address whether MAG is the primary physiological substrate","No in vivo substrate validation"]},{"year":2013,"claim":"Identifying lyso-PS as a principal brain substrate redefined ABHD12's physiological role and linked its loss mechanistically to TLR2-driven microglial activation and PHARC-like phenotypes.","evidence":"Untargeted metabolomics of ABHD12-/- mouse brain, recombinant lyso-PS lipase assay, and knockout behavioral phenotyping; ABPP in patient lymphoblastoid cells","pmids":["23297193","24027063"],"confidence":"High","gaps":["Did not identify the lyso-PS-generating enzyme","Chain-length basis of substrate accumulation not yet explained"]},{"year":2015,"claim":"Placing ABHD12 opposite ABHD16A defined a metabolic axis that sets lyso-PS levels and bidirectionally tunes innate immune output.","evidence":"ABPP, pharmacology, Abhd12-/- and Abhd16a-/- mice, lipidomics, and macrophage cytokine assays","pmids":["25580854"],"confidence":"High","gaps":["Direct physical interaction between the two enzymes not addressed","Tissue-specific contributions not resolved"]},{"year":2016,"claim":"Disease-mutation enzymology plus a rescuable animal model proved that loss of catalytic activity is the cause of the multi-system PHARC phenotype.","evidence":"MAG lipase assays of disease mutants in HEK293, zebrafish morpholino knockdown, and wild-type versus mutant mRNA rescue","pmids":["27890673"],"confidence":"High","gaps":["Mechanism connecting lipid changes to myelination and sensory defects not defined","Morpholino off-target effects inherent to method"]},{"year":2018,"claim":"Defining glycosylation dependence, very-long-chain substrate preference, and ER localization explained the specific lipid species that accumulate on enzyme loss.","evidence":"Substrate library profiling, organelle fractionation, immunofluorescence, and validation in WT and knockout brain membranes; selective inhibitor DO264 in vivo and LCMV infection model","pmids":["30237167","30420694"],"confidence":"High","gaps":["No structural model of substrate selectivity","Receptors mediating in vivo lyso-PS immune effects beyond TLR2 not fully defined"]},{"year":2019,"claim":"Expanding the substrate scope to oxidized PS and lyso-PI tied ABHD12 to oxidative-stress lipid signaling and innate immune suppression.","evidence":"ROS-driven chemical-genetic screen with knockout validation; ABPP-guided inhibitor and substrate assays with cytokine readout in THP-1 macrophages","pmids":["30643283","30720278"],"confidence":"High","gaps":["Relative physiological contribution of each substrate class unresolved","Lyso-PI specificity not independently replicated at same rigor"]},{"year":2020,"claim":"Genetic epistasis and regional and cell-type mapping placed ABHD12 within a Lands-cycle remodeling network and localized its lyso-PS axis activity to the cerebellum, while linking it to ferroptosis.","evidence":"ABHD12-/- x LPCAT3-/- double-knockout lipidomics and phenotyping; cerebellar immunohistochemistry with knockout controls; ferroptosis assays in HT1080 cells","pmids":["32364701","32462874","32195565"],"confidence":"High","gaps":["Causal bioactive lyso-PS species driving PHARC not pinpointed","Ferroptosis mechanism characterized in a single lab"]},{"year":2024,"claim":"Gain-of-function rescue positioned ABHD12-mediated PS metabolism downstream of SARM1 in regulating phagocyte-driven axon degeneration.","evidence":"Transgenic neuronal ABHD12 overexpression in NMNAT2 hypomorphic sarmopathy mice with motor, axon morphology, and macrophage activation readouts","pmids":["40496808","38979309"],"confidence":"Medium","gaps":["Direct lipid mediator linking ABHD12 to axon protection not defined","Single lab study"]},{"year":2026,"claim":"Discovering post-translational control of ABHD12 activity in microglia and dissecting CB2R and PGE2 branches clarified how its 2-AG hydrolysis governs context-dependent immune signaling.","evidence":"ABPP with tailored probe LEI-612, microglial-state lipidomics, DO264 inhibition, CB2R antagonism, and cytokine measurements","pmids":["41983263"],"confidence":"Medium","gaps":["Identity of the post-translational modification regulating activity unknown","Single lab study"]},{"year":null,"claim":"How distinct substrate pools (lyso-PS, ox-PS, 2-AG, lyso-PI) are differentially channeled to specific receptors and pathologies, and the structural basis of very-long-chain selectivity, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental structure of ABHD12","Mechanism partitioning substrate use across cell types and disease contexts undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3,7,9,10]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,9]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[3,7]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[7,13]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,5,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,8,10,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,15]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,12]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N2K0","full_name":"Lysophosphatidylserine lipase ABHD12","aliases":["2-arachidonoylglycerol hydrolase ABHD12","Abhydrolase domain-containing protein 12","hABHD12","Monoacylglycerol lipase ABHD12","Oxidized phosphatidylserine lipase ABHD12"],"length_aa":398,"mass_kda":45.1,"function":"Lysophosphatidylserine (LPS) lipase that mediates the hydrolysis of lysophosphatidylserine, a class of signaling lipids that regulates immunological and neurological processes (PubMed:25290914, PubMed:30237167, PubMed:30420694, PubMed:30643283, PubMed:30720278). Represents a major lysophosphatidylserine lipase in the brain, thereby playing a key role in the central nervous system (By similarity). Also able to hydrolyze oxidized phosphatidylserine; oxidized phosphatidylserine is produced in response to severe inflammatory stress and constitutes a proapoptotic 'eat me' signal (PubMed:30643283). Also has monoacylglycerol (MAG) lipase activity: hydrolyzes 2-arachidonoylglycerol (2-AG), thereby acting as a regulator of endocannabinoid signaling pathways (PubMed:22969151, PubMed:24027063). Has a strong preference for very-long-chain lipid substrates; substrate specificity is likely due to improved catalysis and not improved substrate binding (PubMed:30237167)","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q8N2K0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABHD12","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ABHD12","total_profiled":1310},"omim":[{"mim_id":"617781","title":"RETINITIS PIGMENTOSA 80; RP80","url":"https://www.omim.org/entry/617781"},{"mim_id":"616966","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 6, ACYLGLYCEROL LIPASE; ABHD6","url":"https://www.omim.org/entry/616966"},{"mim_id":"613599","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12, LYSOPHOSPHOLIPASE; ABHD12","url":"https://www.omim.org/entry/613599"},{"mim_id":"612674","title":"POLYNEUROPATHY, HEARING LOSS, ATAXIA, RETINITIS PIGMENTOSA, AND CATARACT; PHARC","url":"https://www.omim.org/entry/612674"},{"mim_id":"609699","title":"MONOGLYCERIDE LIPASE; MGLL","url":"https://www.omim.org/entry/609699"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ABHD12"},"hgnc":{"alias_symbol":["DKFZP434P106","dJ965G21.2","BEM46L2","ABHD12A"],"prev_symbol":["C20orf22"]},"alphafold":{"accession":"Q8N2K0","domains":[{"cath_id":"3.40.50.1820","chopping":"116-289_312-388","consensus_level":"medium","plddt":96.1167,"start":116,"end":388}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N2K0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N2K0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N2K0-F1-predicted_aligned_error_v6.png","plddt_mean":84.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABHD12","jax_strain_url":"https://www.jax.org/strain/search?query=ABHD12"},"sequence":{"accession":"Q8N2K0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N2K0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N2K0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N2K0"}},"corpus_meta":[{"pmid":"21418147","id":"PMC_21418147","title":"The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.","date":"2011","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21418147","citation_count":221,"is_preprint":false},{"pmid":"20797687","id":"PMC_20797687","title":"Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.","date":"2010","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20797687","citation_count":171,"is_preprint":false},{"pmid":"22969151","id":"PMC_22969151","title":"Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22969151","citation_count":150,"is_preprint":false},{"pmid":"23297193","id":"PMC_23297193","title":"ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23297193","citation_count":143,"is_preprint":false},{"pmid":"25580854","id":"PMC_25580854","title":"Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay.","date":"2015","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25580854","citation_count":127,"is_preprint":false},{"pmid":"22938382","id":"PMC_22938382","title":"Targeted next-generation sequencing identifies a homozygous nonsense mutation in ABHD12, the gene underlying PHARC, in a family clinically diagnosed with Usher syndrome type 3.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22938382","citation_count":64,"is_preprint":false},{"pmid":"30643283","id":"PMC_30643283","title":"A chemical-genetic screen identifies ABHD12 as an oxidized-phosphatidylserine lipase.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30643283","citation_count":62,"is_preprint":false},{"pmid":"30420694","id":"PMC_30420694","title":"Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo.","date":"2018","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30420694","citation_count":55,"is_preprint":false},{"pmid":"24697911","id":"PMC_24697911","title":"Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: from syndromic to nonsyndromic retinal degeneration.","date":"2014","source":"Ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/24697911","citation_count":45,"is_preprint":false},{"pmid":"24027063","id":"PMC_24027063","title":"Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24027063","citation_count":43,"is_preprint":false},{"pmid":"32195565","id":"PMC_32195565","title":"Blockade of the Lysophosphatidylserine Lipase ABHD12 Potentiates Ferroptosis in Cancer Cells.","date":"2020","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32195565","citation_count":42,"is_preprint":false},{"pmid":"30720278","id":"PMC_30720278","title":"Discovery and Optimization of Selective and in Vivo Active Inhibitors of the Lysophosphatidylserine Lipase α/β-Hydrolase Domain-Containing 12 (ABHD12).","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30720278","citation_count":36,"is_preprint":false},{"pmid":"27890673","id":"PMC_27890673","title":"Functional validation of ABHD12 mutations in the neurodegenerative disease PHARC.","date":"2016","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/27890673","citation_count":35,"is_preprint":false},{"pmid":"30237167","id":"PMC_30237167","title":"Biochemical characterization of the PHARC-associated serine hydrolase ABHD12 reveals its preference for very-long-chain lipids.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30237167","citation_count":34,"is_preprint":false},{"pmid":"25743180","id":"PMC_25743180","title":"Novel ABHD12 mutations in PHARC patients: the differential diagnosis of deaf-blindness.","date":"2015","source":"The Annals of otology, rhinology, and laryngology","url":"https://pubmed.ncbi.nlm.nih.gov/25743180","citation_count":27,"is_preprint":false},{"pmid":"32462874","id":"PMC_32462874","title":"Mapping the Neuroanatomy of ABHD16A, ABHD12, and Lysophosphatidylserines Provides New Insights into the Pathophysiology of the Human Neurological Disorder PHARC.","date":"2020","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32462874","citation_count":27,"is_preprint":false},{"pmid":"24879289","id":"PMC_24879289","title":"Discovery of triterpenoids as reversible inhibitors of α/β-hydrolase domain containing 12 (ABHD12).","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24879289","citation_count":26,"is_preprint":false},{"pmid":"32364701","id":"PMC_32364701","title":"ABHD12 and LPCAT3 Interplay Regulates a Lyso-phosphatidylserine-C20:4 Phosphatidylserine Lipid Network Implicated in Neurological Disease.","date":"2020","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32364701","citation_count":25,"is_preprint":false},{"pmid":"28448692","id":"PMC_28448692","title":"A complex homozygous mutation in ABHD12 responsible for PHARC syndrome discovered with NGS and review of the literature.","date":"2017","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/28448692","citation_count":24,"is_preprint":false},{"pmid":"29571850","id":"PMC_29571850","title":"Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene.","date":"2018","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29571850","citation_count":20,"is_preprint":false},{"pmid":"30564946","id":"PMC_30564946","title":"Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease.","date":"2018","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/30564946","citation_count":18,"is_preprint":false},{"pmid":"30974196","id":"PMC_30974196","title":"A novel ABHD12 nonsense variant in Usher syndrome type 3 family with genotype-phenotype spectrum review.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30974196","citation_count":16,"is_preprint":false},{"pmid":"32077159","id":"PMC_32077159","title":"Genotype-phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome.","date":"2020","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/32077159","citation_count":16,"is_preprint":false},{"pmid":"32829065","id":"PMC_32829065","title":"Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.","date":"2020","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/32829065","citation_count":16,"is_preprint":false},{"pmid":"34573385","id":"PMC_34573385","title":"The Phenotypic Spectrum of Patients with PHARC Syndrome Due to Variants in ABHD12: An Ophthalmic Perspective.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34573385","citation_count":14,"is_preprint":false},{"pmid":"32366405","id":"PMC_32366405","title":"ABHD12 Knockdown Suppresses Breast Cancer Cell Proliferation, Migration and Invasion.","date":"2020","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32366405","citation_count":13,"is_preprint":false},{"pmid":"38215051","id":"PMC_38215051","title":"Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/38215051","citation_count":11,"is_preprint":false},{"pmid":"37803361","id":"PMC_37803361","title":"Genetic insights into PHARC syndrome: identification of a novel frameshift mutation in ABHD12.","date":"2023","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37803361","citation_count":7,"is_preprint":false},{"pmid":"27245904","id":"PMC_27245904","title":"A Sensitive and Versatile Fluorescent Activity Assay for ABHD12.","date":"2016","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/27245904","citation_count":4,"is_preprint":false},{"pmid":"38053637","id":"PMC_38053637","title":"ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38053637","citation_count":3,"is_preprint":false},{"pmid":"37849541","id":"PMC_37849541","title":"Probing the Interactions of Thiazole Abietane Inhibitors with the Human Serine Hydrolases ABHD16A and ABHD12.","date":"2023","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/37849541","citation_count":3,"is_preprint":false},{"pmid":"40496808","id":"PMC_40496808","title":"Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40496808","citation_count":3,"is_preprint":false},{"pmid":"39123271","id":"PMC_39123271","title":"Genotype-phenotype spectrum and correlation of PHARC Syndrome due to pathogenic ABHD12 variants.","date":"2024","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/39123271","citation_count":2,"is_preprint":false},{"pmid":"38979309","id":"PMC_38979309","title":"Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38979309","citation_count":2,"is_preprint":false},{"pmid":"39910854","id":"PMC_39910854","title":"A Novel Compound Heterozygous Variant in the ABHD12 Gene Cause PHARC Syndrome in a Chinese Family: The Proband Presenting New Genotype and Phenotype.","date":"2025","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39910854","citation_count":1,"is_preprint":false},{"pmid":"41983263","id":"PMC_41983263","title":"Stimulus-Driven Remodeling of Microglial Endocannabinoid Metabolism Illuminates ABHD12 Function in Immunity.","date":"2026","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41983263","citation_count":0,"is_preprint":false},{"pmid":"42083571","id":"PMC_42083571","title":"Multi-Omics Characterization of ABHD12 Across Pan-Cancer and Validation of Its Role in Promoting Proliferation and Metastasis in Breast Cancer.","date":"2026","source":"Breast cancer (Dove Medical Press)","url":"https://pubmed.ncbi.nlm.nih.gov/42083571","citation_count":0,"is_preprint":false},{"pmid":"42174523","id":"PMC_42174523","title":"Potentially functional variants of CYP2A6 and ABHD12 in the arachidonic acid metabolism pathway genes predict the survival of HBV-related hepatocellular carcinoma patients.","date":"2026","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/42174523","citation_count":0,"is_preprint":false},{"pmid":"41189896","id":"PMC_41189896","title":"Case Report: novel GUCA1B and ABHD12 mutations in retinitis pigmentosa sine pigmento: expanding the genotypic spectrum through multimodal phenotyping.","date":"2025","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41189896","citation_count":0,"is_preprint":false},{"pmid":"39826350","id":"PMC_39826350","title":"Generation of a human iPSC line (UCLi025-A) from a patient with PHARC syndrome harbouring biallelic variants in ABHD12.","date":"2025","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39826350","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21599,"output_tokens":4348,"usd":0.065008,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12389,"output_tokens":3574,"usd":0.075648,"stage2_stop_reason":"end_turn"},"total_usd":0.140656,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"ABHD12 was identified as the gene mutated in PHARC disease, and the encoded enzyme hydrolyzes 2-arachidonoylglycerol (2-AG), the main endocannabinoid lipid transmitter acting on cannabinoid receptors CB1 and CB2, establishing PHARC as an inborn error of endocannabinoid metabolism.\",\n      \"method\": \"Human genetics (mutation identification) combined with published biochemical data on 2-AG hydrolase activity\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic causation established in 19 patients across four countries, combined with enzymatic function replicated independently across multiple subsequent studies\",\n      \"pmids\": [\"20797687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ABHD12 is highly expressed in microglia and accounts for approximately 9% of total brain 2-AG hydrolase activity, positioning it as a serine hydrolase that degrades the endocannabinoid 2-AG in the brain.\",\n      \"method\": \"Activity-based biochemical assays of brain 2-AG hydrolase activity combined with expression profiling\",\n      \"journal\": \"Acta physiologica (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative enzyme activity assays in brain tissue, replicated in subsequent biochemical characterization papers, but review article compiling data\",\n      \"pmids\": [\"21418147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Human ABHD12 is a genuine monoacylglycerol (MAG) lipase with preference for the 1(3)- and 2-isomers of arachidonoylglycerol; the catalytic triad residues S246-D333-H372 are essential for enzymatic activity and for labeling by the active-site serine-directed probe TAMRA-FP, as shown by site-directed mutagenesis abolishing both activity and probe labeling.\",\n      \"method\": \"Fluorescent glycerol assay with recombinant human ABHD12; site-directed mutagenesis of catalytic triad; activity-based protein profiling with TAMRA-FP\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis of catalytic residues, multiple orthogonal methods (fluorescent assay + ABPP probe) in a single study\",\n      \"pmids\": [\"22969151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABHD12 is a principal lysophosphatidylserine (LPS) lipase in the mammalian brain; recombinant ABHD12 exhibits robust LPS lipase activity, ABHD12-/- mice show massive accumulation of very-long-chain LPS lipids that are TLR2 activators, and loss of ABHD12 leads to microglial activation followed by auditory and motor defects resembling PHARC.\",\n      \"method\": \"Untargeted metabolomics of ABHD12-/- mouse brain; recombinant protein LPS lipase activity assay; genetic mouse model with behavioral phenotyping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted enzymatic activity with recombinant protein, validated in knockout mouse metabolomics, multiple orthogonal methods, replicated by subsequent studies\",\n      \"pmids\": [\"23297193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss-of-function mutations in ABHD12 result in absence of ABHD12 hydrolase activity as measured by activity-based protein profiling (ABPP) of serine hydrolases in patient-derived lymphoblastoid cell lines, and heterozygous deletion causes ~50% reduction in ABHD12 activity, confirming that mutations directly impair enzyme function.\",\n      \"method\": \"Activity-based protein profiling (ABPP) of serine hydrolases in patient-derived lymphoblastoid cell lines; quantitative RT-PCR\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ABPP in patient cells with quantitative activity measurement, two orthogonal methods (ABPP + qRT-PCR), single lab\",\n      \"pmids\": [\"24027063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABHD16A functions as a phosphatidylserine (PS) lipase that generates lyso-PS in mammalian systems, and ABHD12 degrades lyso-PS; these two enzymes form an ABHD16A-ABHD12 axis that dynamically regulates lyso-PS metabolism in vivo. In mouse macrophages, disruption of ABHD12 increases lyso-PS levels and enhances LPS-induced cytokine production, while ABHD16A disruption has the opposite effect.\",\n      \"method\": \"Activity-based protein profiling; pharmacological inhibition; genetic knockouts (Abhd12-/- and Abhd16a-/- mice); lipidomics; cytokine measurements in macrophages\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (ABPP, pharmacology, genetics, lipidomics, functional immunological assays), two knockout mouse models, independent validation\",\n      \"pmids\": [\"25580854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ABHD12 mutations (T253R, T202I, R352*) abolish monoacylglycerol lipase activity in transfected HEK293 cells; knockdown of zebrafish abhd12 causes myelination defects, progressive ataxia, motor impairment, retinal architecture disruption, lens clarification inhibition, and reduced mechanosensory hair cells — phenotypes rescued by wild-type human ABHD12 mRNA but not by mutation-harboring mRNAs.\",\n      \"method\": \"MAG lipase activity assay in transfected HEK293 cells; zebrafish morpholino knockdown; mRNA rescue experiments with wild-type vs. mutant ABHD12\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic activity assay with disease mutations, zebrafish loss-of-function with specific phenotypes, and rescue with wild-type vs. mutant mRNA as functional validation\",\n      \"pmids\": [\"27890673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ABHD12 requires glycosylation for optimal enzymatic activity and has a strong preference for very-long-chain lipid substrates; ABHD12 is enriched on the endoplasmic reticulum membrane, as shown by cellular organelle fractionation and immunofluorescence, explaining the accumulation of very-long-chain LPS lipids in ABHD12 knockout mouse brains.\",\n      \"method\": \"Biochemical substrate profiling with a lipid library of varying chain lengths; cellular organelle fractionation; immunofluorescence; validation in brain membrane lysates from WT and ABHD12-/- mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with substrate library, subcellular fractionation with functional consequence (ER localization explaining VLC lipid accumulation), validated in knockout mouse tissue\",\n      \"pmids\": [\"30237167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Pharmacological inhibition of ABHD12 with the selective inhibitor DO264 elevates lyso-PS in mouse brain and primary human macrophages, and both DO264-treated and ABHD12-/- mice display heightened immunological responses to LCMV infection with severe lung pathology and elevated proinflammatory chemokines, demonstrating that ABHD12 regulates immunostimulatory lyso-PS lipid pathways in vivo.\",\n      \"method\": \"Selective small-molecule inhibitor (DO264) in vivo; ABHD12-/- mice; viral infection model (LCMV); lipidomics; cytokine/chemokine measurements\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological and genetic approaches with concordant results, in vivo lipidomics, immune functional readouts, replicated across two independent perturbation strategies\",\n      \"pmids\": [\"30420694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ABHD12 hydrolyzes oxidized phosphatidylserine (ox-PS), a proapoptotic 'eat me' signal generated under oxidative stress; this activity was identified via a chemical-genetic screen and validated in primary peritoneal macrophages and brains from Abhd12-/- mice under inflammatory stress.\",\n      \"method\": \"Chemical-genetic screen using a ROS-generating small molecule; lipidomics; validation in primary macrophages and Abhd12-/- mouse brain under inflammatory conditions\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — unbiased chemical-genetic screen combined with in vitro and in vivo validation in knockout mice, multiple orthogonal methods\",\n      \"pmids\": [\"30643283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ABHD12 acts on both lysophosphatidylserine (lyso-PS) and lysophosphatidylinositol (lyso-PI) as substrates; the selective inhibitor DO264 augments inflammatory cytokine production from human THP-1 macrophage cells, confirming that ABHD12 enzymatic activity suppresses innate immune responses.\",\n      \"method\": \"Activity-based protein profiling (ABPP)-guided inhibitor development; substrate assays with lyso-PS and lyso-PI; cytokine production assay in human THP-1 macrophages\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ABPP-guided pharmacology with functional immune readout, but substrate specificity for lyso-PI not independently replicated at same rigor\",\n      \"pmids\": [\"30720278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Genetic deletion of the lysophospholipid acyltransferase LPCAT3 blocks accumulation of brain arachidonoyl (C20:4) PS in ABHD12-/- mice while producing hyper-increases in lyso-PS, demonstrating that ABHD12 and LPCAT3 coordinately regulate lyso-PS and C20:4 PS content in the CNS through a Lands cycle-like remodeling pathway; lyso-PS lipids are identified as likely bioactive metabolites contributing to PHARC neuropathologies.\",\n      \"method\": \"Double-knockout mouse model (ABHD12-/- × LPCAT3-/-); brain lipidomics; auditory function testing; microgliosis assessment\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis using double-knockout mice with lipidomics and functional phenotyping, multiple orthogonal readouts in a single rigorous study\",\n      \"pmids\": [\"32364701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pharmacological inhibition or genetic disruption of ABHD12 potentiates ferroptosis in HT1080 cancer cells induced by the GPX4 inhibitor RSL3; ABHD12-inactivated cells show elevated lyso-PS, increased arachidonate (C20:4)-containing PS, and elevated 2-AG, identifying ABHD12 as a regulator of ferroptotic sensitivity through oxidation-sensitive lipid mediators.\",\n      \"method\": \"Small-molecule screen with serine hydrolase inhibitors; ABHD12 genetic disruption; metabolomics in RSL3-treated cells; ferroptosis cell death assays\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic approaches with metabolomic validation, but ferroptosis mechanism is partially characterized in a single lab study\",\n      \"pmids\": [\"32195565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Using immunohistochemistry with ABHD16A and ABHD12 knockout mice as controls, ABHD12 and ABHD16A are shown to localize to distinct regions and cell types in the cerebellum; cerebellar lyso-PS levels are most affected by deletion of ABHD12 (increased) or ABHD16A (decreased), establishing the cerebellum as the brain region where the ABHD16A-ABHD12 lyso-PS axis is most active.\",\n      \"method\": \"Immunohistochemistry with knockout mouse controls; subcellular organelle fractionation; mass spectrometry-based quantitative lipidomics of brain regions\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with genetic controls plus quantitative regional lipidomics, but single lab study\",\n      \"pmids\": [\"32462874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Neuronal overexpression of ABHD12 (a PS lipase) suppresses macrophage activation, preserves motor axon integrity, and rescues motor function in a chronic SARM1-activation (sarmopathy) mouse model, demonstrating that ABHD12-mediated PS metabolism regulates phagocyte-mediated axon elimination downstream of SARM1 activation.\",\n      \"method\": \"Transgenic neuronal overexpression of ABHD12 in NMNAT2 hypomorphic mouse model; motor function behavioral assays; axon morphology analysis; macrophage activation assessment\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain-of-function with functional rescue and mechanistic pathway placement, but single lab study with published and preprint versions\",\n      \"pmids\": [\"40496808\", \"38979309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In microglia, ABHD12 activity is uncoupled from transcript and protein expression levels (indicative of post-translational regulation); cellular ABHD12 activity inversely correlates with 2-AG levels, and pharmacological inhibition of ABHD12 elevates 2-AG, reduces arachidonic acid (AA), and modulates cytokine release through dual mechanisms: CB2R-dependent suppression of TNF-α and PGE2-dependent regulation of IL-6.\",\n      \"method\": \"Activity-based protein profiling (ABPP) with tailored probe LEI-612; targeted lipidomics across microglial states; pharmacological inhibition with DO264; CB2R antagonism; cytokine measurements\",\n      \"journal\": \"ACS chemical neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ABPP with tailored probe combined with lipidomics and pharmacological dissection of downstream signaling, multiple orthogonal methods in single lab study\",\n      \"pmids\": [\"41983263\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABHD12 is an integral membrane serine hydrolase (catalytic triad S246-D333-H372) localized to the endoplasmic reticulum that functions as a principal lysophosphatidylserine (lyso-PS) lipase with preference for very-long-chain and arachidonoyl-containing substrates, also hydrolyzing 2-arachidonoylglycerol (2-AG) and oxidized phosphatidylserine; it acts in an ABHD16A-ABHD12 metabolic axis that dynamically regulates lyso-PS levels in the brain (particularly cerebellum), and its loss leads to accumulation of proinflammatory TLR2-activating lyso-PS lipids, microglial activation, and the progressive PHARC neuropathology, while its activity in microglia is post-translationally regulated and controls 2-AG-mediated immunosuppression via CB2R and PGE2 pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABHD12 is an integral endoplasmic reticulum membrane serine hydrolase that degrades bioactive lysophospholipids and endocannabinoids, thereby controlling neuroinflammation and the lipid signals that drive PHARC neuropathology [#0, #3, #7]. Catalysis depends on a serine hydrolase triad (S246-D333-H372), whose mutation abolishes both enzymatic activity and active-site probe labeling [#2]. Although first characterized as a 2-arachidonoylglycerol (2-AG) hydrolase that contributes to brain endocannabinoid turnover [#0, #1, #2], its principal physiological role is as a lysophosphatidylserine (lyso-PS) lipase with strong preference for very-long-chain substrates, a selectivity reinforced by its glycosylation-dependent activity and ER localization [#3, #7]; it additionally hydrolyzes oxidized phosphatidylserine and lysophosphatidylinositol [#9, #10]. ABHD12 operates within an ABHD16A-ABHD12 axis—ABHD16A generating lyso-PS and ABHD12 degrading it—that dynamically sets lyso-PS tone, most prominently in the cerebellum, and coordinates with the Lands-cycle remodeler LPCAT3 to balance lyso-PS and arachidonoyl-PS pools [#5, #11, #13]. Loss of ABHD12 causes accumulation of proinflammatory TLR2-activating lyso-PS lipids, microglial activation, and progressive auditory and motor defects modeling PHARC, and ABHD12 was identified as the gene mutated in PHARC disease [#0, #3]. Functionally, ABHD12 restrains innate immune and phagocyte responses: its activity suppresses inflammatory cytokine production, modulates ferroptotic sensitivity, regulates phagocyte-mediated axon elimination downstream of SARM1, and in microglia is post-translationally controlled to govern 2-AG-mediated immunosuppression via CB2R and PGE2 pathways [#8, #12, #14, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing the disease link and an enzymatic activity converted an uncharacterized gene into a defined inborn error of lipid metabolism, framing PHARC as a hydrolase deficiency.\",\n      \"evidence\": \"Human genetics mutation identification combined with biochemical 2-AG hydrolase data\",\n      \"pmids\": [\"20797687\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish which lipid substrate is pathophysiologically relevant\", \"No subcellular localization or structural detail\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defining the catalytic triad and confirming monoacylglycerol lipase activity pinned the molecular basis of catalysis and licensed activity-based profiling of the enzyme.\",\n      \"evidence\": \"Recombinant human ABHD12 fluorescent glycerol assay, catalytic-triad mutagenesis, and TAMRA-FP activity-based profiling\",\n      \"pmids\": [\"22969151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address whether MAG is the primary physiological substrate\", \"No in vivo substrate validation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying lyso-PS as a principal brain substrate redefined ABHD12's physiological role and linked its loss mechanistically to TLR2-driven microglial activation and PHARC-like phenotypes.\",\n      \"evidence\": \"Untargeted metabolomics of ABHD12-/- mouse brain, recombinant lyso-PS lipase assay, and knockout behavioral phenotyping; ABPP in patient lymphoblastoid cells\",\n      \"pmids\": [\"23297193\", \"24027063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the lyso-PS-generating enzyme\", \"Chain-length basis of substrate accumulation not yet explained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placing ABHD12 opposite ABHD16A defined a metabolic axis that sets lyso-PS levels and bidirectionally tunes innate immune output.\",\n      \"evidence\": \"ABPP, pharmacology, Abhd12-/- and Abhd16a-/- mice, lipidomics, and macrophage cytokine assays\",\n      \"pmids\": [\"25580854\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between the two enzymes not addressed\", \"Tissue-specific contributions not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Disease-mutation enzymology plus a rescuable animal model proved that loss of catalytic activity is the cause of the multi-system PHARC phenotype.\",\n      \"evidence\": \"MAG lipase assays of disease mutants in HEK293, zebrafish morpholino knockdown, and wild-type versus mutant mRNA rescue\",\n      \"pmids\": [\"27890673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting lipid changes to myelination and sensory defects not defined\", \"Morpholino off-target effects inherent to method\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defining glycosylation dependence, very-long-chain substrate preference, and ER localization explained the specific lipid species that accumulate on enzyme loss.\",\n      \"evidence\": \"Substrate library profiling, organelle fractionation, immunofluorescence, and validation in WT and knockout brain membranes; selective inhibitor DO264 in vivo and LCMV infection model\",\n      \"pmids\": [\"30237167\", \"30420694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of substrate selectivity\", \"Receptors mediating in vivo lyso-PS immune effects beyond TLR2 not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Expanding the substrate scope to oxidized PS and lyso-PI tied ABHD12 to oxidative-stress lipid signaling and innate immune suppression.\",\n      \"evidence\": \"ROS-driven chemical-genetic screen with knockout validation; ABPP-guided inhibitor and substrate assays with cytokine readout in THP-1 macrophages\",\n      \"pmids\": [\"30643283\", \"30720278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological contribution of each substrate class unresolved\", \"Lyso-PI specificity not independently replicated at same rigor\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic epistasis and regional and cell-type mapping placed ABHD12 within a Lands-cycle remodeling network and localized its lyso-PS axis activity to the cerebellum, while linking it to ferroptosis.\",\n      \"evidence\": \"ABHD12-/- x LPCAT3-/- double-knockout lipidomics and phenotyping; cerebellar immunohistochemistry with knockout controls; ferroptosis assays in HT1080 cells\",\n      \"pmids\": [\"32364701\", \"32462874\", \"32195565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal bioactive lyso-PS species driving PHARC not pinpointed\", \"Ferroptosis mechanism characterized in a single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Gain-of-function rescue positioned ABHD12-mediated PS metabolism downstream of SARM1 in regulating phagocyte-driven axon degeneration.\",\n      \"evidence\": \"Transgenic neuronal ABHD12 overexpression in NMNAT2 hypomorphic sarmopathy mice with motor, axon morphology, and macrophage activation readouts\",\n      \"pmids\": [\"40496808\", \"38979309\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct lipid mediator linking ABHD12 to axon protection not defined\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Discovering post-translational control of ABHD12 activity in microglia and dissecting CB2R and PGE2 branches clarified how its 2-AG hydrolysis governs context-dependent immune signaling.\",\n      \"evidence\": \"ABPP with tailored probe LEI-612, microglial-state lipidomics, DO264 inhibition, CB2R antagonism, and cytokine measurements\",\n      \"pmids\": [\"41983263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the post-translational modification regulating activity unknown\", \"Single lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct substrate pools (lyso-PS, ox-PS, 2-AG, lyso-PI) are differentially channeled to specific receptors and pathologies, and the structural basis of very-long-chain selectivity, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental structure of ABHD12\", \"Mechanism partitioning substrate use across cell types and disease contexts undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3, 7, 9, 10]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 5, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 8, 10, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 15]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}